Clinical performance is complex and often involves multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for effectiveness and adverse reactions, adapted to the timely schedule according to the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HLP-associated cells. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.